<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524823</url>
  </required_header>
  <id_info>
    <org_study_id>HP 7-251 S</org_study_id>
    <nct_id>NCT00524823</nct_id>
  </id_info>
  <brief_title>Early Detection of Prostate Cancer by FACS</brief_title>
  <acronym>FACS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Ziv Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziv Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early detection of prostrate cancer and development of metastases. The research will attempt
      to match the SCM test (structuredness of the cytoplasmic matrix) in lymphocytes as an early
      cancer detection test using Florescent Activated Cell Sorting (FACS) as a replacement for the
      CellScan instrument. The test is based on measurement of cellular changes in response to the
      specific prostate antigen, PSA.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Hyperplasia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Case</arm_group_type>
    <description>10 diagnosed men in age 60 - 90 with Prostate Cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Case</arm_group_type>
    <description>10 patients with benign growth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Control</arm_group_type>
    <description>10 health volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Control</arm_group_type>
    <description>10 patients diagnosed with other cancer</description>
  </arm_group>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Experimental group : Males between the ages of 60-90 years, with medical diagnosis of
        prostate cancer according to both clinical and hematological examinations, before receiving
        any medical treatment.

        Control Group 1: Males between the ages of 60-90 years, with diagnosed benign prostate
        hyperplasia -BPH.

        Control Group 2: Males between the ages of 60-90 years, medically diagnosed as healthy.

        Control Group 3: Males between the ages of 60-90 years, medically diagnosed with another
        form of cancer, not prostate.

        Exclusion Criteria:

        Experimental group: Other known cancer or systemic infection. Control Group 1: Other known
        cancer or systemic infection. Control Group 2:Past hematological disorders nor cancer
        growth history. other known systemic infection, nor urinary tract infection. Patients
        hospitalized for orthopedic injuries of any type who are otherwise free of urinary tract
        infections.

        Control Group 3:Other known systemic infection, nor urinary tract infection.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Kucherski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziv Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina Kucherski, MD</last_name>
    <phone>050-8434041</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yihia Johari, MD</last_name>
    <phone>050-8434094</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urology Department, Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>20100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yihia Johari, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yihia Johari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Klein O, Lin S, Embon O, Sazbon A, Zidan J, Kook AI. An approach for high sensitivity detection of prostate cancer by analysis of changes in structuredness of the cytoplasmic matrix of lymphocytes specifically induced by PSA-ACT. J Urol. 1999 Jun;161(6):1994-6.</citation>
    <PMID>10332488</PMID>
  </reference>
  <reference>
    <citation>Altman, Roberta. The prostate Answer Book. Warner Books, lnc., 1993.</citation>
  </reference>
  <reference>
    <citation>American Cancer Society. National Cnference on Prostate Cancer. Philadelphia, Pennsylvania: September/October 1994.</citation>
  </reference>
  <reference>
    <citation>Rous, Stephen N., M.D.; The prostate Book. W.W. Norton &amp; Co., 1992.</citation>
  </reference>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <last_update_submitted>September 4, 2007</last_update_submitted>
  <last_update_submitted_qc>September 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2007</last_update_posted>
  <keyword>Prostate Cancer</keyword>
  <keyword>Hyperplasia - BPH</keyword>
  <keyword>FACS</keyword>
  <keyword>Prostate Cancer, Hyperplasia - BPH, Malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

